24
Mar
2020
What Not To Do: Lessons From Spain’s Cavalier Response to COVID-19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2020
Doctor, Mother, CEO: Balancing Competing Needs, and Opting for the Front Lines
Yesterday I woke up on an island. I am temporarily – but purposefully — isolating myself and my two children, ages 10 and 12, in a familiar place that carries with it a slower rhythm from a different time. It’s our second home. It also happens that, on the first day of spring, there are still no cases of suspected... Read More
24
Mar
2020
Digital Tools in Clinical Trials Find Opportunity During Pandemic
The current crisis represents a potentially defining moment for at least some health technologies and technology-enabled services. Telehealth, as discussed in my last column, is one conspicuous example, and the jury is still out. The potential benefit seems especially striking at a time when so many Americans are being told to stay at home, yet there are also serious concerns,... Read More